ArticleCureus2026
Potential of Thiocolchicoside as an Antimicrobial Repurposing Agent: An In Vitro Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) is a global health emergency that poses a hazard to the effective management of infectious diseases. Drug repurposing provides a cost-effective and expeditious solution by identifying new applications for existing pharmaceuticals. A semi-synthetic derivative of colchicoside, thiocolchicoside (THC), has been recently investigated for its potential anticancer and antimicrobial properties. It is prescribed as a muscle relaxant. THC was tested against a variety of gram-positive and gram-negative bacteria, as well as fungal isolates, at concentrations ranging from 4000 to 62.5 µg/mL. Standard antibacterial and antifungal controls were provided by gentamicin (GN) and fluconazole (FZ). Turbidity and absorbance-based assays at 600 nm were employed to ascertain the minimum inhibitory concentrations (MICs). THC demonstrated MICs of 125 µg/mL against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.